Literature DB >> 34927075

Orexin receptors in GtoPdb v.2021.3.

Paul Coleman1, Luis de Lecea2, Anthony Gotter1, Jim Hagan3, Daniel Hoyer4, Thomas Kilduff5, Jyrki P Kukkonen6, Rod Porter3, John Renger1, Jerome M Siegel7, Gregor Sutcliffe2, Neil Upton3, Christopher J Winrow1.   

Abstract

Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [42]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [109]. Currently the only orexin receptor ligands in clinical use are suvorexant and lemborexant, which are used as hypnotics. Orexin receptor crystal structures have been solved [134, 133, 54, 117, 46].

Entities:  

Year:  2021        PMID： 34927075      PMCID： PMC8682808          DOI： 10.2218/gtopdb/f51/2021.3

Source DB:  PubMed          Journal:  IUPHAR BPS Guide Pharm CITE        ISSN： 2633-1020


  136 in total

1.  Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists.

Authors:  Laura C McAtee; Steven W Sutton; Dale A Rudolph; Xiaobing Li; Leah E Aluisio; Victor K Phuong; Curt A Dvorak; Timothy W Lovenberg; Nicholas I Carruthers; Todd K Jones
Journal:  Bioorg Med Chem Lett       Date:  2004-08-16       Impact factor: 2.823

Review 2.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 3.  International Union of Pharmacology. XLVI. G protein-coupled receptor list.

Authors:  Steven M Foord; Tom I Bonner; Richard R Neubig; Edward M Rosser; Jean-Phillipe Pin; Anthony P Davenport; Michael Spedding; Anthony J Harmar
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

4.  Orexin receptors couple to Ca2+ channels different from store-operated Ca2+ channels.

Authors:  J P Kukkonen; K E Akerman
Journal:  Neuroreport       Date:  2001-07-03       Impact factor: 1.837

5.  Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

Authors:  Romano Di Fabio; Annalisa Pellacani; Stefania Faedo; Adelheid Roth; Laura Piccoli; Philip Gerrard; Rod A Porter; Christopher N Johnson; Kevin Thewlis; Daniele Donati; Luigi Stasi; Simone Spada; Geoffrey Stemp; David Nash; Clive Branch; Leanda Kindon; Mario Massagrande; Alessandro Poffe; Simone Braggio; Elisabetta Chiarparin; Carla Marchioro; Emiliangelo Ratti; Mauro Corsi
Journal:  Bioorg Med Chem Lett       Date:  2011-06-30       Impact factor: 2.823

6.  Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists.

Authors:  Da-Thao Tran; Pascal Bonaventure; Michael Hack; Taraneh Mirzadegan; Curt Dvorak; Michael Letavic; Nicholas Carruthers; Timothy Lovenberg; Steven W Sutton
Journal:  Eur J Pharmacol       Date:  2011-06-12       Impact factor: 4.432

7.  Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex.

Authors:  Emmanouil Karteris; Rachel J Machado; Jing Chen; Sevasti Zervou; Edward W Hillhouse; Harpal S Randeva
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-01-25       Impact factor: 4.310

8.  Orexin-A-induced Ca2+ entry: evidence for involvement of trpc channels and protein kinase C regulation.

Authors:  Kim P Larsson; Hanna M Peltonen; Genevieve Bart; Lauri M Louhivuori; Annika Penttonen; Miia Antikainen; Jyrki P Kukkonen; Karl E O Akerman
Journal:  J Biol Chem       Date:  2004-11-10       Impact factor: 5.157

9.  A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache.

Authors:  I Rainero; S Gallone; W Valfrè; M Ferrero; G Angilella; C Rivoiro; E Rubino; P De Martino; L Savi; M Ferrone; L Pinessi
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

10.  LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.

Authors:  Thomas E Fitch; Mark J Benvenga; Cynthia D Jesudason; Charity Zink; Amy B Vandergriff; Michelle M Menezes; Douglas A Schober; Linda M Rorick-Kehn
Journal:  Front Neurosci       Date:  2014-01-28       Impact factor: 4.677
View more
  2 in total

Review 1.  Orexin Signaling: A Complex, Multifaceted Process.

Authors:  Natasha C Dale; Daniel Hoyer; Laura H Jacobson; Kevin D G Pfleger; Elizabeth K M Johnstone
Journal:  Front Cell Neurosci       Date:  2022-04-13       Impact factor: 6.147

2.  Cholinergic feedback to bipolar cells contributes to motion detection in the mouse retina.

Authors:  Chase B Hellmer; Leo M Hall; Jeremy M Bohl; Zachary J Sharpe; Robert G Smith; Tomomi Ichinose
Journal:  Cell Rep       Date:  2021-12-14       Impact factor: 9.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.